Huizinga Robert Bindert's Form 4 filing
Aurinia Pharmaceuticals Inc. (AUPH) · filed Mar 4, 2022
- Accession no.
- 0001628280-22-005118
- Filed
- Mar 4, 2022
- Trade date
- Mar 2, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $58.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Huizinga Robert BindertCIK 0001837648 | Officer (EVP of Research) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2022 | Common Stock | AGrant or awardAcquired | +8,500 | $0.00 | $0 | 74,228 | Direct | |
| Mar 2, 2022 | Common Stock | SSaleDisposed | −4,849 | $12.01 | −$58,236.49 | 69,379 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2022 | Common Shares | AGrant or awardAcquired | +62,448 | $0.00 | $0 | 62,448 | Direct | |
| Mar 2, 2022 | Common Stock | AGrant or awardAcquired | +106,838 | $0.00 | $0 | 106,838 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.